Kabi, Mylan and Neptune Thwarted In US Pemetrexed Proceedings

StopSign
A US Court of Appeals ruling has halted potential generics of Lilly's Alimta pemetrexed brand until 2022 • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Legal & IP

More from Generics Bulletin